{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:10Z","timestamp":1793140330152,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104176","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:53:30Z","timestamp":1787982810000},"page":"104176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA"],"prefix":"10.1016","volume":"99","author":[{"given":"Zhejia","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas M.","family":"Willerding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai M.","family":"Schmidt-Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Melk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-565X","authenticated-orcid":false,"given":"Bernhard M.W.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104176_bib1","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.eclinm.2026.104176_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.eclinm.2026.104176_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-022-01173-w","article-title":"The burden of resistant hypertension across the world","volume":"24","author":"Brant","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.eclinm.2026.104176_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.eclinm.2026.104176_bib6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","article-title":"Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system","volume":"88","author":"Sim","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eclinm.2026.104176_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/HJH.0b013e32835b6be7","article-title":"The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study","volume":"31","author":"Shimbo","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15020","article-title":"The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review","volume":"15","author":"Loveman","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eclinm.2026.104176_bib9","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib13","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2026.104176_bib17","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.104176_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40256-025-00738-9","article-title":"Meta-analysis of the effect of semaglutide on blood pressure in obese populations","volume":"25","author":"Li","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.eclinm.2026.104176_bib19","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.eclinm.2026.104176_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102789","article-title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","volume":"75","author":"Jarade","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2026.104176_bib21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104176_bib22","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.104176_bib23","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.eclinm.2026.104176_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11154-014-9299-3","article-title":"Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk","volume":"15","author":"Mathieu","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eclinm.2026.104176_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf035","article-title":"Mechanisms and treatment of obesity-related hypertension-part 2: treatments","volume":"18","author":"Parvanova","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.eclinm.2026.104176_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.eclinm.2026.104176_bib28","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.eclinm.2026.104176_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-Based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib31","series-title":"Fundamentals of Biostatistics","author":"Rosner","year":"2011"},{"key":"10.1016\/j.eclinm.2026.104176_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2021.04.047","article-title":"Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease","volume":"334","author":"Groenland","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurjpc\/zwad066","article-title":"Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry","volume":"30","author":"Ebinger","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib35","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/HJH.0000000000000023","article-title":"Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study","volume":"32","author":"Tsioufis","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib37","first-page":"681","article-title":"Epidemiology of resistant hypertension in Canada","volume":"38","author":"Leung","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.104176_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104176_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib42","article-title":"Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis","volume":"359","author":"Ma","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.104176_bib43","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2026.104176_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","article-title":"Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials","volume":"43","author":"Wong","year":"2025","journal-title":"J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib45","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/jcm11112998","article-title":"Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Barboza","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.104176_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf236.127","article-title":"Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis","author":"Basile","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","article-title":"Endogenous activation of glucagon-like Peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na+\/H+ exchanger isoform 3, renal angiotensin II, and insulin sensitivity","volume":"76","author":"Martins","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.eclinm.2026.104176_bib48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.eclinm.2026.104176_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49364-x","article-title":"Central glucagon-like Peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats","volume":"9","author":"Katsurada","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.104176_bib50","article-title":"GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications","author":"Moiz","year":"2025","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.eclinm.2026.104176_bib51","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.eclinm.2026.104176_bib52","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1530\/JME-16-0025","article-title":"Adipocytes, aldosterone and obesity-related hypertension","volume":"57","author":"Dinh Cat","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.eclinm.2026.104176_bib53","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.eclinm.2026.104176_bib54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","article-title":"Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction","volume":"146","author":"Elkholey","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib55","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eclinm.2026.104176_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.104176_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41371-024-00983-6","article-title":"Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement","volume":"39","author":"Faconti","year":"2025","journal-title":"J Hum Hypertens"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:34:41Z","timestamp":1793136881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"alternative-id":["S2589537026004293"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104176","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104176"}}